PARTNERSHIPS
Partner with us
We are committed to developing best-in-class therapeutics for immunological and inflammatory diseases and welcome the opportunity to explore collaborations with potential partners around the world.
Partners
Celexor Bio, a biotechnology company dedicated to developing MAG-018 (CLXR-901), an ILT7-targeting monoclonal antibody, was established through a successful partnership between Miragene and Aditum Bio. Celexor holds an exclusive worldwide license from Miragene for MAG-018, and Miragene also holds an equity stake in Celexor. Through this partnership, Miragene retains a meaningful stake in the program’s future success.
Miragene has in-licensed exclusive worldwide rights to MAG-007 from HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13). MAG-007 is a next-generation BTK inhibitor with best-in-class potential for the treatment of immunologic and inflammatory diseases. Miragene leads and funds the program, and MAG-007 is currently in global clinical development.
Triptych Therapeutics, an MPM-incubated biotechnology company, has licensed worldwide rights to MAG-013, an IL-7Rα-targeting monoclonal antibody, from Miragene.
To explore partnership opportunities, please contact our business development team by emailing bdpartner@miragene.com.